Skip to content

Effect of isopropyl alcohol nasal inhalation and intravenous Ondansetron versus placebo on nausea and vomiting in patients with head trauma

Effect of isopropyl alcohol nasal inhalation and intravenous Ondansetron versus placebo on nausea and vomiting in patients with head trauma: a randomized clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20120215009014N225
Enrollment
228
Registered
2018-06-21
Start date
2018-06-22
Completion date
Unknown
Last updated
2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head trauma. Post-traumatic headache

Interventions

Intervention 1: Intervention group 1: Inhalation of pad impregnated with isopropyl alcohol 70% for one minute at a maximum of 3 times at 2 minutes intervals. Intervention 2: Intervention group 2: Intr

Sponsors

Hamedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age of 12 to 80 years Light head trauma GCS 14 to 15 Having nausea and vomiting

Exclusion criteria

Exclusion criteria: Severe trauma to other parts of the body Patients with sensitivity to isopropyl alcohol inhalation or Ondansetron Inhalation disorder Mental disorder

Design outcomes

Primary

MeasureTime frame
Assessing the severity of nausea and vomiting. Timepoint: Before intervention and 2, 4, 6, and 10 min after intervention. Method of measurement: Using visual analog scale (VAS).

Secondary

MeasureTime frame
Assessing the severity of headache. Timepoint: Before intervention and 2, 4, 6, and 10 min after intervention. Method of measurement: Using visual analog scale (VAS).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Fatemeh Gholami Goodarzi

Hamedan University of Medical Sciences

f.gholamigudarzi@yahoo.com+98 81 3364 0030

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026